Arginine Cardio by Dr. Rainer Böger

© Arginine Benefits LLC, 2013Author: Dr. Rainer Böger Page 1

Arginine Cardio: Evidence-based reduction of blood pressure (1)

L-Arginine is the precursor of Nitric Oxide

L-Citrulline potentiates the bioavailability of L-arginine

Arginine Cardio is the L-Arginine supplement that has the highest L-citrullineContent

Nitric Oxide causes vasodilation and thereby reduces blood pressure.



L-Arginine is not being marketed by pharmaceutical industrywith a multi million dollar budget for promotion.

Clinical trials with L-arginine to lower blood pressure have been performedby independent academic research institutions, with small research budgets.

Therefore, patient numbers in clinical trials with L-arginine are comparatively small.

However, there is a recent meta-analysis summarizing clinical trials with L-arginine.


Dong et al.; American Heart Journal 2011

11 randomized, double-blind, placebo-controlled trials involving 387 participants

with oral L-arginine intervention ranging from 4 to 24 g/d

[…] Compared with placebo, L-arginine intervention significantly lowered

systolic blood pressure by 5.39 mm Hg (95% CI −8.54 to −2.25, P = .001) and

diastolic BP by 2.66 mm Hg (95% CI −3.77 to −1.54, P = .001).




L-Arginine better Placebo better



L-Arginine better Placebo better




Arginine Cardio: Evidence-based reversal of atherosclerosis (1)

Nitric Oxide has been known to protect from atherosclerosis ever sincethe Nobel Prize for Medicine was awarded for this finding in 1998.

L-Arginine is the precursor of Nitric Oxide. Animal experiments have unequivocally proven in different models and in various laboratories around the world that L-arginine can reverse atheroslcerosis.

Whilst no big, multinational studies could be performed with L-arginine due tolack of funding from public sources, multiple studies have shown reversal ofendothelial dysfunction, the early clinical sign of atherosclerosis, by L-arginine.

We have a collection of case reports that show reversal of atherosclerotic plaquein humans during a few months of L-arginine intake.


Böger et al., Atherosclerosis 1995; 117: 273 – 284

Study A: Prevention of Plaque Build-Up

Design:

0 8 weeks

Control

Cholesterol

Cholesterol + L-Arginine

Results:

Cholesterol

Cholesterol; treated with L-arginineCONTROL CHOLESTEROL

0

5

10

15

20

25

30

35

40

45

50

55

60

Ca

roti

d i

nti

ma

l p

laq

ue

are

a

[%

of

tota

l in

tim

a]

*

CHOL.

+ L-ARGININE

#

(0)

A. carotis


Böger et al., Circulation 1997; 96: 1282-1290

Study B: Stopping the Progression of Plaque Build-Up

Design:

0 10 weeks

Control

Cholesterol

Results:

164


Cholesterol

Cholesterol + Lovastatin

Control

0 weeks164

Inti

mal

pla

qu

e ar

ea(c

aro

tid

art

ery)

[%

]

0

50

40

30

20

10

-92%

„Dietary L-arginine completely suppressed

the aggravation of intimal plaque formation

during the second part of the study

Lovastatin treatment significantly reduced

the progression of plaque formation but did

not completely block it.“


Candipan et al., Arterioscler. Thromb. Vasc. Biol. 1996; 16: 44-50

Study C: Reversal of Pre-Existing Plaque

Design:

0 18 weeks

Cholesterol

Results:

2310

Cholesterol


0 weeks2310

Inti

mal

pla

qu

e ar

ea(c

aro

tid

art

ery)

[%

]

0

75

60

45

30

15

„This is the first demonstration that

restoration of NO activity can induce

regression of preexisting intimal lesions

and provides evidence that L-arginine therapy

may be of potential clinical benefit “

Cholesterol

1814




Arginine Cardio by Dr. Rainer Böger

Documents